• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Lexicon Pharmaceuticals Inc.

    2/17/26 4:01:25 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LXRX alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    Intentional misstatements or omissions of fact constitute federal criminal violations. See 18 U.S.C. 1001.

    FORM D

    Notice of Exempt Offering of Securities
    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001062822
    LEXICON PHARMACEUTICALS, INC./DE
    LEXICON GENETICS INC/TX
    Lexicon Genetics Inc./TX
    LEXICON PHARMACEUTICALS, INC./DE
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    LEXICON PHARMACEUTICALS, INC.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    LEXICON PHARMACEUTICALS, INC.
    Street Address 1 Street Address 2
    2445 Technology Forest Blvd., 11th Floor
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    The Woodlands TEXAS 77381 281-863-3000

    3. Related Persons

    Last Name First Name Middle Name
    Debbane Raymond
    Street Address 1 Street Address 2
    2445 Technology Forest Blvd., 11th Floor
    City State/Province/Country ZIP/PostalCode
    The Woodlands TEXAS 77381
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Amouyal Phillipe J.
    Street Address 1 Street Address 2
    2445 Technology Forest Blvd., 11th Floor
    City State/Province/Country ZIP/PostalCode
    The Woodlands TEXAS 77381
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Barker Samuel
    Street Address 1 Street Address 2
    2445 Technology Forest Blvd., 11th Floor
    City State/Province/Country ZIP/PostalCode
    The Woodlands TEXAS 77381
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Cheung Ivan H.
    Street Address 1 Street Address 2
    2445 Technology Forest Blvd., 11th Floor
    City State/Province/Country ZIP/PostalCode
    The Woodlands TEXAS 77381
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Coiante Scott
    Street Address 1 Street Address 2
    2445 Technology Forest Blvd., 11th Floor
    City State/Province/Country ZIP/PostalCode
    The Woodlands TEXAS 77381
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Crum Brian T.
    Street Address 1 Street Address 2
    2445 Technology Forest Blvd., 11th Floor
    City State/Province/Country ZIP/PostalCode
    The Woodlands TEXAS 77381
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    DeFrancesco Lisa
    Street Address 1 Street Address 2
    2445 Technology Forest Blvd., 11th Floor
    City State/Province/Country ZIP/PostalCode
    The Woodlands TEXAS 77381
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Exton Mike
    Street Address 1 Street Address 2
    2445 Technology Forest Blvd., 11th Floor
    City State/Province/Country ZIP/PostalCode
    The Woodlands TEXAS 77381
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Martens Rachel
    Street Address 1 Street Address 2
    2445 Technology Forest Blvd., 11th Floor
    City State/Province/Country ZIP/PostalCode
    The Woodlands TEXAS 77381
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Gopinathan Suma
    Street Address 1 Street Address 2
    2445 Technology Forest Blvd., 11th Floor
    City State/Province/Country ZIP/PostalCode
    The Woodlands TEXAS 77381
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Granowitz Craig B.
    Street Address 1 Street Address 2
    2445 Technology Forest Blvd., 11th Floor
    City State/Province/Country ZIP/PostalCode
    The Woodlands TEXAS 77381
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Martens Rachel
    Street Address 1 Street Address 2
    2445 Technology Forest Blvd., 11th Floor
    City State/Province/Country ZIP/PostalCode
    The Woodlands TEXAS 77381
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    McDermott Wendy E.
    Street Address 1 Street Address 2
    2445 Technology Forest Blvd., 11th Floor
    City State/Province/Country ZIP/PostalCode
    The Woodlands TEXAS 77381
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Sobecki Christopher
    Street Address 1 Street Address 2
    2445 Technology Forest Blvd., 11th Floor
    City State/Province/Country ZIP/PostalCode
    The Woodlands TEXAS 77381
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Sullivan Diane E.
    Street Address 1 Street Address 2
    2445 Technology Forest Blvd., 11th Floor
    City State/Province/Country ZIP/PostalCode
    The Woodlands TEXAS 77381
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Swain Judith L.
    Street Address 1 Street Address 2
    2445 Technology Forest Blvd., 11th Floor
    City State/Province/Country ZIP/PostalCode
    The Woodlands TEXAS 77381
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
       Biotechnology
       Health Insurance
       Hospitals & Physicians
    X Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2026-02-02    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
       Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    Street Address 1 Street Address 2
    City State/Province/Country ZIP/Postal Code
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $59,150,000 USD
    or    Indefinite
    Total Amount Sold $55,668,255 USD
    Total Remaining to be Sold $3,481,745 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    Total Offering Amount includes gross proceeds from the private placement of common stock and the issuance of convertible preferred securities, including a partially exercised option to purchase additional convertible preferred securities.

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    1

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    Lexicon Pharmaceuticals, Inc. /s/ Brian T. Crum Brian T. Crum Senior Vice President and General Counsel 2026-02-17

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $LXRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LXRX

    DatePrice TargetRatingAnalyst
    3/5/2025$2.00 → $1.00Outperform → Market Perform
    Leerink Partners
    6/17/2024$10.00Buy
    H.C. Wainwright
    4/30/2024$5.00Outperform
    Leerink Partners
    3/7/2023$3.00Hold
    Jefferies
    8/12/2022$10.00Overweight
    Piper Sandler
    More analyst ratings

    $LXRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lexicon Pharma downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Lexicon Pharma from Outperform to Market Perform and set a new price target of $1.00 from $2.00 previously

    3/5/25 7:37:06 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Lexicon Pharma with a new price target

    H.C. Wainwright initiated coverage of Lexicon Pharma with a rating of Buy and set a new price target of $10.00

    6/17/24 7:36:12 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Lexicon Pharma with a new price target

    Leerink Partners initiated coverage of Lexicon Pharma with a rating of Outperform and set a new price target of $5.00

    4/30/24 6:26:57 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LXRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Invus Global Management, Llc was granted 22,400,000 shares, bought $2,000,001 worth of shares (1,538,462 units at $1.30) and was granted 367,145 units of Series B Convertible Preferred Stock (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/4/26 4:25:05 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Coats Lonnel bought $94,797 worth of shares (90,000 units at $1.05), increasing direct ownership by 11% to 914,359 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    11/17/23 4:55:09 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Coats Lonnel bought $10,100 worth of shares (10,000 units at $1.01), increasing direct ownership by 1% to 824,359 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    11/13/23 5:31:49 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LXRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by SVP, Human Resources Mcdermott Wendy

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/17/26 4:10:59 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by SVP, Partnerships & Corp Strat Martens Rachel Yap

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/17/26 4:10:18 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by SVP, Chief Medical Officer Granowitz Craig B

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/17/26 4:09:31 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LXRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

    THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) ("Lexicon") today announced the closing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001, and concurrent private placement of 22,400,000 shares of common stock and 367,145 shares of series b convertible preferred stock (the "Series B Convertible Preferred Stock"). The shares of common stock offered pursuant to the public offering were sold at a public offering price of $1.30 per share and the shares of preferred stock were sold at a price of $65 per share. The offerings closed on February 2, 2026. In addition to the shares s

    2/6/26 5:17:00 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

    THE WOODLANDS, Texas, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) ("Lexicon") today announced the pricing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001. The shares of common stock being offered pursuant to the public offering are being offered at a public offering price of $1.30 per share. All of the shares are being offered by Lexicon. The gross proceeds from the public offering are expected to be $41.6 million, before deducting underwriting discounts and commissions and other offering expenses. The public offering is expected to close on or about February 2, 2026, subject to the satisf

    1/30/26 2:50:25 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lexicon Announces Proposed Public Offering of Common Stock

    THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) ("Lexicon") today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001. In addition, Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of common stock. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. Jefferies and Piper Sandler are acting as joint book-running managers for the proposed offering. Concurrently with the closing of the underwrit

    1/29/26 4:31:19 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LXRX
    SEC Filings

    View All

    SEC Form PRE 14A filed by Lexicon Pharmaceuticals Inc.

    PRE 14A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)

    2/17/26 4:12:08 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by Lexicon Pharmaceuticals Inc.

    D - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)

    2/17/26 4:01:25 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form FWP filed by Lexicon Pharmaceuticals Inc.

    FWP - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

    2/6/26 5:17:30 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LXRX
    Leadership Updates

    Live Leadership Updates

    View All

    Lexicon Appoints Scott Coiante as Chief Financial Officer

    THE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the appointment of Scott Coiante as senior vice president and chief financial officer, effective today, January 2, 2025. Mr. Coiante is a senior finance executive with more than 35 years of experience in the life science and pharmaceutical industries. He joins Lexicon from Agile Therapeutics, where he served as the senior vice president, chief financial officer and treasurer of Agile Therapeutics Inc. from August 2023 to August 2024, as well as from 2011-2019. "I am pleased to join Lexicon at this pivotal moment for the company and eager to contribute to its

    1/2/25 8:00:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lexicon Appoints Ivan H. Cheung to Board of Directors

    THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors. Mr. Cheung is a biopharmaceutical executive with more than 25 years of experience in the healthcare industry and a proven track record of shareholder value creation. He is currently the chief executive officer and a director of NextPoint Therapeutics, and he has served as senior advisor to TPG Growth – a growth investing platform within global asset manager TPG – since September 2023. "I am honored to join the Lexicon Board of Directors at this pivotal moment in the company's history, and to support its mis

    11/20/24 4:05:47 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director

    THE WOODLANDS, Texas, July 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that the Lexicon Board of Directors has appointed Mike Exton, Ph.D. as chief executive officer and director of Lexicon. Dr. Exton succeeds Lonnel Coats who, as previously announced, retired effective July 7, 2024. Dr. Exton most recently served as the global cardiometabolic therapeutic head at Novartis. "I am confident that Mike is the right person to serve as Lexicon's next chief executive officer at this critical time for the company," said Ray Debbane, chairman of Lexicon's board of directors. "He is an inspiring leader with a demonstrated track record of success, includi

    7/8/24 9:15:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LXRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for INPEFA issued to LEXICON PHARMACEUTICALS INC

    Submission status for LEXICON PHARMACEUTICALS INC's drug INPEFA (ORIG-1) with active ingredient SOTAGLIFLOZIN has changed to 'Approval' on 05/26/2023. Application Category: NDA, Application Number: 216203, Application Classification: Type 1 - New Molecular Entity

    5/30/23 10:02:49 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LXRX
    Financials

    Live finance-specific insights

    View All

    Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

    FDA End-of-Phase 2 meeting for pilavapadin in DPNP to be held by year-end All IND-enabling studies of LX9851 for obesity completed and submitted to licensee Novo Nordisk Site initiation for SONATA-HCM Phase 3 study of sotagliflozin in both obstructive and non-obstructive HCM completed; enrollment completion on target for 2026 Additional data in support of potential resubmission of Zynquista for type 1 diabetes submitted to FDA Conference call and webcast at 8:30 am ET   THE WOODLANDS, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended September 30, 2025, and provided an update on key corpo

    11/6/25 7:30:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

    THE WOODLANDS, Texas, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its third quarter 2025 financial results on Thursday, November 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company's website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast

    10/30/25 8:30:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

    Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo Nordisk expected to submit IND Enrollment completion for SONATA Phase 3 study in both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) on target for 2026 Conference call and webcast at 8:30 am ET   THE WOODLANDS, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended June 30, 2025, and provided an update on key corporate milestones and accomplishments.  "We continue t

    8/6/25 7:30:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LXRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lexicon Pharmaceuticals Inc.

    SC 13D/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

    12/9/24 9:33:20 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lexicon Pharmaceuticals Inc.

    SC 13G/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

    11/14/24 4:26:14 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lexicon Pharmaceuticals Inc.

    SC 13G/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

    11/12/24 10:32:10 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care